BofA raised the firm’s price target on Fulcrum Therapeutics (FULC) to $7 from $6 and keeps an Underperform rating on the shares after the company presented partial Cohort 4 data at ASH from its ongoing Phase 1b PIONEER study assessing pociredir in severe sickle cell disease. The firm assumes a potential 2029 launch in SCD with $1.5B in nominal peak sales by 2038, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
- Fulcrum Therapeutics announces $150M offering of common stock
- Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
- Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
- Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital